Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVO crawled time : 19:00 save search
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published: 2024-03-08 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
| Email alert
Add to watchlist
wegovy obesity disease approved risk cardiovascular
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2024-02-06 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.54%
H: 2.31%
C: 1.44%
Global Generic Drugs Business Analysis Report 2023-2030: Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
Published: 2023-10-23 (Crawled : 19:00) - prnewswire.com
ENDPQ | News | $0.0007 -50.0% 1K
|
n/a
|
| O: -44.44%
H: 60.0%
C: -20.0%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 1.37%
H: 1.36%
C: 1.36%
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 0.45%
H: 2.46%
C: 1.67%
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.79%
H: 1.41%
C: 1.21%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
BAX | $41.02 1.54% 0.0% 2.6M
|
Health Technology
|
| O: 0.2%
H: 0.9%
C: -1.05%
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: -1.82%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.38%
H: 2.31%
C: 2.02%
report business global growth
Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.84%
H: 0.19%
C: -0.13%
il-22 obesityweek pharma control preclinical
Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity
Published: 2023-09-20 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -1.92%
H: 0.61%
C: -1.74%
obesity initiative global
Global Insulin Pen Market Projected to Reach $73.39 Billion by 2028 with Steady CAGR of 5.25% during 2023-2028
Published: 2023-07-28 (Crawled : 19:00) - prnewswire.com
TRUMY | $16.94 0.79% 52K
|
Manufacturing
| Email alert
Add to watchlist
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
TRUMF | $16.488 -17.59% 1.7K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
reach global insulin market
Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024
Published: 2023-03-14 (Crawled : 19:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.15%
H: 0.65%
C: 0.56%
diabetes living insulin
Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2023-02-02 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 2.58%
H: 1.24%
C: 0.77%
Novo Nordisk A/S – Share repurchase programme
Published: 2022-11-30 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.25%
H: 0.2%
C: -0.02%
repurchase
Global $19 Billion Home-Use Insulin Delivery Devices Markets, 2015-2020 & 2021-2030
Published: 2021-12-20 (Crawled : 19:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.2%
H: 1.62%
C: 1.37%
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
|
| O: 0.45%
H: 2.78%
C: 1.68%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
BDX | $234.36 0.21% 0.0% 800K
|
Health Technology
|
| O: 0.57%
H: 0.63%
C: -0.8%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.76%
H: 0.67%
C: 0.45%
PODD | $167.18 1.68% 1.65% 550K
|
Health Technology
|
| O: 0.29%
H: 3.22%
C: 3.08%
device liver insulin
Novo Nordisk announces supply challenges for Wegovy® in the US
Published: 2021-12-17 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
wegovy
Novo Nordisk A/S – Share repurchase programme
Published: 2021-11-29 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -1.04%
H: 1.43%
C: 0.79%
Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
Published: 2021-06-04 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
| Email alert
Add to watchlist
therapy
Global Hematology Drugs Market (2021 to 2030) - COVID-19 Impact and Recovery
Published: 2021-04-13 (Crawled : 19:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 0.64%
H: 0.06%
C: -0.94%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.47%
H: 1.1%
C: -0.62%
covid drug
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.